Table 3.
Diagnosis | Number of samples | % of samples showing cyclin D1 mRNA overexpression | Range of relative normalized cyclin D1 quantity |
---|---|---|---|
Mantle cell lymphoma | 10 | 80% | 0.611–62.25 |
Chronic lymphocytic leukemia/small lymphocytic lymphoma | 11 | 0% | 0.00064–0.395 |
Hairy cell leukemia | 3 | 0% | 0.0063–0.0105 |
Follicular lymphoma (grades I & II) | 6 | 0% | 0.066–0.702 |
Anaplastic large cell lymphoma | 3 | 0% | 0.014–0.0415 |
Peripheral T-cell lymphoma | 3 | 33% | 0.110–6.63 |
Other non-Hodgkin’s lymphomas | 6 | 0% | 0.0091–0.165 |
Precursor acute lymphoblastic leukemia/lymphoma | 15 | 0% | 9.02E-07–0.078 |
Reactive follicular hyperplasia | 5 | 0% | 0.0204–1.00 |
Reactive peripheral blood lymphocytes | 6 | 0% | 9.64E-05–0.00012 |
Samples with a normalized cyclin D1 expression level greater than 1.00 were defined as over-expressing cyclin D1 mRNA.
Other Non-Hodgkin’s lymphomas included Burkitt (n = 1), Burkitt-like lymphoma (n = 4), and plasmacytoma (n = 1).